ECTRIMS 2026: DMT Advances and Treatment Monitoring in RRMS

Author profile image Aggregator
0 comments
Dr Shiv Saidha explores MS data on BTK inhibitors, discordant JCV testing for natalizumab treatment, and why peripartum biomarker elevations may not signal disease activity.
Medscape

Source: Medscape Neurology Published 29 Oct 2026 Imported 02 Nov 2026 Relevancy: Not reviewed

Read the article